Point72 Hong Kong LTD Syndax Pharmaceuticals Inc Transaction History

Point72 Hong Kong LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $32,054 - $45,778	-2,350 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $34,874 - $52,052	2,350 New	2,350 $41,000
Q4 2021 Feb 14, 2022	SELL	$15.23 - $22.47 $9,945 - $14,672	-653 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.87 - $19.8 $46,187 - $65,934	-3,330 Reduced 83.61%	653 $12,000
Q2 2021 Aug 16, 2021	BUY	$13.42 - $25.18 $48,781 - $91,529	3,635 Added 1044.54%	3,983 $68,000
Q1 2021 May 17, 2021	BUY	$19.28 - $24.59 $6,709 - $8,557	348 New	348 $8,000
Q4 2020 Feb 16, 2021	SELL	$15.1 - $26.44 $2,869 - $5,023	-190 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$13.39 - $17.48 $73,752 - $96,279	-5,508 Reduced 96.67%	190 $3,000
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $50,940 - $119,544	5,698 New	5,698 $84,000

227

88.3M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $910M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.